April 6, 2020

Jvion Names Industry Veteran Jay Deady as Chief Executive Officer

Former CEO Shantanu Nigam transitions to new role as Executive Chairman of the Board

Atlanta, GA – April 6, 2020 – Jvion, a leader in clinical AI, announced today that Jay Deady, former CEO of Recondo (acquired by Waystar) and Awarepoint (now part of CenTrak), will succeed founder Shantanu Nigam as Jvion’s Chief Executive Officer. Shantanu will transition to his new role as Executive Chairman of the Board. Jay’s demonstrated leadership in healthcare IT will help scale the company through the next stage of growth, while Shantanu will continue to support Jvion as Executive Chairman of the Board.

“With a proven track record of leading innovators in AI for healthcare, Jay is uniquely qualified to carry on our mission to prevent avoidable patient harm,” said Shantanu. “He shares our values and purpose and will help maintain everything that sets Jvion apart. It’s been an honor founding and building Jvion and I’m looking forward to working with Jay as we scale the company and grow the impact of the Jvion AI CORE across the care continuum.”

Jay Deady has been a leader, product visionary, and innovator in healthcare IT for nearly 30  years. Jay’s most recent role was as CEO of Recondo, a leading AI revenue cycle company, where he and the team focused on growth and product innovation that ultimately moved Recondo from last to first in KLAS client satisfaction.  Recondo was acquired by Waystar in December 2019. Prior to Recondo, Jay served as CEO of Awarepoint, a clinical technology and software company, where he grew the company into the leading technology provider in the caregiver and patient asset-flow and capacity-management market.  Prior to Awarepoint, Jay held leadership positions at Eclipsys (now Allscripts), McKesson Provider Technologies, Cerner Corporation and ADAC Healthcare.

“AI is transforming healthcare. Shantanu and his fellow co-founders have done an excellent job building a team and developing the technology to accelerate that transformation,” said Jay. “Jvion has achieved incredible results in advancing clinical AI that can impact patient lives, augment clinical decisioning and lower the costs of care. The company is uniquely positioned as a result of its ability to deliver both predictive to prescriptive insights and real-time interventions within existing clinical workflows. It was an easy decision to join this amazing team, and I look forward to championing Jvion as it leads the next wave of clinical AI adoption.”

Shantanu has led Jvion since 2010, when he founded the company to address the pervasive problem of preventable patient harm. His passion for AI and building innovative teams has led Jvion from a startup to the market leader in clinical AI, with the Jvion AI CORE deployed in about 50 health systems and over 300 hospitals across the country. As Executive Chairman of the Board, Shantanu will continue to influence Jvion’s direction as he finds new avenues to champion the use of AI in healthcare.

In the midst of the COVID-19 pandemic, Jay joins Jvion during a turbulent time for healthcare. As CEO, he will lead Jvion’s ongoing efforts to support hospitals and providers through the crisis. Jvion recently released two solutions to help its customers and the community more broadly. The COVID Community Vulnerability Map is a publicly available tool to help community health leaders strategize a proactive pandemic response to protect vulnerable populations. Also available is it’s AI-powered COVID Vulnerability Patient List ranks hospital patient populations based on risk for the most severe outcomes post infection.  Patients are classified by their risk of hospitalization, end organ failure, and mortality as a result of infection.

About Jvion

Jvion enables healthcare organizations to prevent avoidable patient harm and lower costs through its AI-enabled prescriptive analytics solution. An industry first, the Jvion Machine goes beyond simple predictive analytics and machine learning to identify patients on a trajectory to becoming high risk and for whom intervention will likely be successful. Jvion determines the interventions that will more effectively reduce risk and enable clinical action. And it accelerates time to value by leveraging established patient-level intelligence to drive engagement across hospitals, populations, and patients. To date, the Jvion Machine has been deployed across about 50 hospital systems and 300 hospitals, who report average reductions of 30% for preventable harm incidents and annual cost savings of $6.3 million. For more information, visit www.jvion.com.

Jvion PR Contact:
Lexi Herosian